These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 32961435)
1. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435 [TBL] [Abstract][Full Text] [Related]
2. Discovery of novel Bcr-Abl Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413 [TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-((3-amino- El-Damasy AK; Kim HJ; Park JW; Nam Y; Hur W; Bang EK; Keum G J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2228515. PubMed ID: 37470410 [TBL] [Abstract][Full Text] [Related]
4. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine. Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
6. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026 [TBL] [Abstract][Full Text] [Related]
7. Discovery of a Candidate Containing an ( Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors. Pan X; Liu N; Liu Y; Zhang Q; Wang K; Liu X; Zhang J Eur J Med Chem; 2022 Aug; 238():114425. PubMed ID: 35561654 [TBL] [Abstract][Full Text] [Related]
9. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476 [TBL] [Abstract][Full Text] [Related]
10. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker. Pan X; Dong J; Shi Y; Shao R; Wei F; Wang J; Zhang J Org Biomol Chem; 2015 Jul; 13(25):7050-66. PubMed ID: 26052668 [TBL] [Abstract][Full Text] [Related]
12. Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation. Wang S; Chen J; Hou R; Xiong Y; Shi H; Chen Z; Li J; Wang X Chem Biol Interact; 2024 Nov; 403():111248. PubMed ID: 39332790 [TBL] [Abstract][Full Text] [Related]
13. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors. Kale MA; Sonwane GM Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase. Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429 [TBL] [Abstract][Full Text] [Related]
15. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules. Cao R; Wang Y; Huang N J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568 [TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665 [TBL] [Abstract][Full Text] [Related]
19. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156 [TBL] [Abstract][Full Text] [Related]
20. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations. Melge AR; Kumar LG; K P; Nair SV; K M; C GM J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]